key: cord-0719175-n9xtegbh authors: Lam, J. Y.; Roberts, S. C.; Shimizu, C.; Bainto, E.; Sivilay, N.; Tremoulet, A. H.; Gardiner, M. A.; Kanegaye, J. T.; Hogan, A. H.; Salazar, J. C.; Mohandas, S.; Szmuszkovicz, J. R.; Mahanta, S.; Dionne, A.; Newburger, J. W.; Ansusinha, E.; DeBiasi, R. L.; Hao, S.; Ling, X. B.; Cohen, H. J.; Nemati, S.; Burns, J. C.; Pediatric Emergency Medicine Kawasaki Disease Research Group,; Group, CHARMS Study title: Multicenter Validation of a Machine Learning Algorithm for Diagnosing Pediatric Patients with Multisystem Inflammatory Syndrome and Kawasaki Disease date: 2022-02-08 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2022.02.07.21268280 sha: baca88e34b67e27493cc4cddc8841401bca018c1 doc_id: 719175 cord_uid: n9xtegbh Multisystem inflammatory syndrome in children (MIS-C) is a novel disease identified during the COVID-19 pandemic characterized by systemic inflammation following SARS-CoV-2 infection. Delays in diagnosing MIS-C may lead to more severe disease with cardiac dysfunction or death. Most pediatric patients recover fully with anti-inflammatory treatments, but early detection of MIS-C remains a challenge given its clinical similarities to Kawasaki disease (KD) and other acute childhood illnesses. We present KIDMATCH (KawasakI Disease vs Multisystem InflAmmaTory syndrome in CHildren), a deep learning algorithm for screening patients for MIS-C, KD, or other febrile illness. KIDMATCH incorporates a conformal prediction framework to tag patients with erroneous data or distribution shifts, enhancing the model generalizability and confidence by flagging unfamiliar cases as indeterminate instead of making spurious predictions. Using routinely collected clinical and laboratory data, KIDMATCH achieved a high area under the curve [0.95-0.98]. Additional external validation of this model on MIS-C patients from 16 hospitals across the United States achieved a positive detection rate of over 90%. Our algorithm has the potential to aid frontline clinicians with distinguishing between MIS-C, KD, and similar febrile illnesses in a timely manner to allow prompt treatment and prevent severe complications. As the coronavirus disease pandemic spread, reports of children with SARS-CoV-2-associated multisystem inflammatory conditions emerged [1] [2] [3] [4] [5] [6] . Clinical features of this new disorder, named Multisystem Inflammatory Syndrome in Children (MIS-C), include fever, gastrointestinal symptoms, and elevated inflammatory markers 7 . Complications may include shock and multiorgan failure. According to the Centers for Disease Control and Prevention (CDC), a total of 5,973 MIS-C cases and 52 MIS-C deaths have been reported nationwide as of November 30, 2021 8 . Despite its low prevalence, MIS-C is a serious condition with potential to cause life-threatening illness, and the lack of a specific diagnostic test makes recognizing MIS-C a challenge. Treatments for MIS-C include intravenous immunoglobulin (IVIG), corticosteroids, and antiinflammatory biologic agents that rely on timely diagnosis of MIS-C to be most effective 9 . Kawasaki disease (KD) is an acute pediatric illness of unknown cause characterized by inflammation of the coronary arteries associated with fever and clinical criteria including rash, conjunctival injection, changes in lips or oropharyngeal mucosa, cervical lymphadenopathy, and changes in peripheral extremities 10 . Many of these clinical features overlap with MIS-C 11 . In response to the difficulty clinicians have in diagnosing and differentiating MIS-C and KD, we applied artificial intelligence (AI) to distinguish among children with MIS-C, KD, and other febrile illnesses characterized by similar clinical and laboratory features. Although there are reported differences such as older age, lower platelet count, and elevated inflammatory markers in MIS-C patients, none of these features alone was sufficient to diagnose MIS-C 4 . Currently, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 there is no published machine learning algorithm to differentiate between KD and MIS-C that has been externally validated. We developed a two-stage AI model to classify patients as having MIS-C, KD, or other febrile illness using clinical signs and laboratory values that would be available at the time of a patient's initial evaluation (Figure 1 ). Pediatric patients with other febrile illness, designated as febrile children (FC), were chosen based on the presence of fever and clinical or laboratory features suggestive of MIS-C and KD. The model in Stage 1 was trained to differentiate between MIS-C and other pediatric febrile conditions. The model in Stage 2 was trained to further classify patients falling into the "other" category as KD or other pediatric febrile illness. Since KD and MIS-C data distributions may vary across different sites, we incorporated a conformal prediction framework within the model 12 . Conformal prediction reduces false alarms by identifying unfamiliar samples in new patient populations when compared to the training cohort and assigns indeterminate labels rather than making spurious predictions. The laboratory tests incorporated into KIDMATCH are commonly obtained for pediatric patients in many outpatient and inpatient medical settings, and the clinical features would be easily assessable by frontline clinicians. The use of such readily available data enables KIDMATCH to be potentially deployable immediately across the United States without the need for specialized laboratory tests. MIS-C patients were defined according to the CDC case definition 17 and enrolled from May 14, 2020 to June 18, 2021. All MIS-C patients had positive antibody testing for either the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 nucleocapsid or spike protein of SARS-CoV-2 and none had received a SARS-CoV-2 vaccine. KD patients met the case definition of the American Heart Association 18 for either complete or incomplete KD. In order to avoid the potential for misclassification, all KD subjects were enrolled from 2009-2019 prior to the pandemic. All KD subjects were diagnosed and treated by one of two highly experienced KD clinicians (J.C.B. and A.H.T.). FC subjects were also enrolled from 2009-2019 and met the following case definition: previously healthy child with fever for at least 3 days plus at least one of the clinical criteria for KD. Over 50% of the FC were referred for evaluation because of a clinical suspicion for KD. The final diagnoses for the FC were adjudicated 2-3 months after enrollment by two experienced pediatric clinicians who reviewed the clinical outcomes in the medical record and all available test results (Supplemental Table 3) . A viral syndrome was defined as a self-limited illness that resolved without treatment and without apparent sequelae. Written consent or assent as appropriate was obtained from parents and subjects and the study was approved by the Institutional Review Boards (IRB) of the University of California San Diego (UCSD), Connecticut Children's Medical Center, Children's Hospital Los Angeles, Boston Children's Hospital, and Children's National Hospital. UCSD served as the central IRB of record for the CHARMS study participants. We used age, the five classical clinical KD signs, and 17 laboratory measurements as features for KIDMATCH based on guidance from the clinician collaborators and availability of laboratory test results for the majority of the training cohort. The five clinical signs were rash, conjunctival injection, changes in lips or oropharyngeal mucosa, cervical lymphadenopathy, and changes in peripheral extremities. Laboratory data included white blood count, age-adjusted hemoglobin, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 platelets, polymorphonuclears or neutrophils, bands, lymphocytes, atypical lymphocytes, monocytes, eosinophils, absolute neutrophil count, absolute band count, erythrocyte sedimentation rate, C-reactive protein, alanine aminotransferase, gamma-glutamyl transferase, albumin, and sodium ( Table 1, Supplementary Table 2 ). Due to the absence of bands and atypical lymphocytes in patients with automated differentials for the complete blood count, an indicator variable was added for the type of differential (0 = manual, 1 = automated). For samples with automated differentials, we imputed the values for bands, atypical lymphocytes, and absolute band counts using the mean of the respective feature. Outlier values defined as less than the 0.5 th percentile or greater than the 99.5 th percentile were set to the values of 0.5 th percentile if lower or 99.5 th percentile if higher. All other missing laboratory values were imputed using K-nearest neighbors as the mean of the respective feature for the 10 most similar samples from the training data. Data were normalized for each laboratory feature except hemoglobin by applying normalization transformations and then subtracting the mean and dividing by the standard deviation. Hemoglobin was normalized for age. In KIDMATCH, we implemented a conformal prediction framework to reject out of distribution samples 12 and separated the classification into two stages (Figure 1) . If a test sample was rejected by the conformal prediction framework, no prediction was calculated. In Stage 1, the model calculated an MIS-C risk score between 0 and 1 for test samples with 1 being the highest MIS-C risk. In Stage 2, the model calculated a KD risk score between 0 and 1 where 1 is the highest risk for KD. Thresholds for each stage were set during internal validation to identify 95% of the MIS-C and KD cases in the test set for Stage 1 and Stage 2, respectively. We trained a feedforward neural network on each of the stages using Tensorflow v.2.3.1 with a logistic regression using scikit-learn v0.24.2 as the baseline model. For both stages, the neural network was trained with the Adam optimizer at a learning rate of 0.01 and equally weighted batches of 100 and 200 samples from each class for Stage 1 and Stage 2, respectively. Each neural network consisted of an input layer (23 units), a single hidden layer (12 units, ReLu activation function, L2 regularization, 20% dropout rate), and a softmax output layer (2 units, binary cross entropy loss function). We split the patients into training and test cohorts using an 80:20 split and employed a 10-fold cross validation to assess performance. Patients with any missing values were not considered for the test set. All patients were used from the training cohort in Stage 1 while MIS-C patients were omitted from the training cohort in Stage 2. Performance of the models were evaluated using accuracy, area under the receiver operating characteristic curve (AUC), positive predictive value (PPV), negative predictive value (NPV), false positive rate (FPR), and false negative rate (FNR) calculated at a minimum 95% sensitivity for the MIS-C and KD classifications for Stage 1 and Stage 2 respectively. The trust sets used in the conformal prediction framework were constructed by filtering patients in the training cohort who had more than one missing value and MIS-C risk scores greater than the 95 th percentile (Supplementary Table 1) . We then constructed a trust set for each of the three classifications (FC, KD, MIS-C) using patients from the training set. Finally, 200 randomly All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint sampled patients were used for the FC and KD trust sets, and all MIS-C patients were used for the MIS-C trust set. We generated feature representations for the conformal prediction framework by passing the normalized features of the training samples through the first hidden layer of the neural network. Feature representations from the test samples were compared to each of the conformal trust sets using cosine similarity, and if a test sample was rejected by all three trust sets, then the model did not calculate risk scores for the test sample. To explain the model predictions, we calculated the Shapley values for the test set using the SHAP Python library 13 . Normalized data from the training set was used as the background to compare normalized test set data for Stage 1 and Stage 2. 100 random background samples were used to calculate the Shapley values for each feature in the internal test set. P-values were calculated by the Mann-Whitney test for continuous variables between two groups, the Kruskal-Wallis test for three groups, the Chi-square test for categorical variables within the cohort used for internal validation, and the DeLong test 19 for AUC. A total of 1517 patients diagnosed from January 1, 2009 to October 1, 2021 with MISC (n=69), KD (n=775), or other febrile illnesses (n=673) were identified from a REDCap database at the Kawasaki Disease Research Center in the University of California San Diego (UCSD). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Laboratory tests and clinical signs were obtained at the time of initial evaluation and prior to treatment for all patients. To improve the generalizability of the model, we added MIS-C patients from Connecticut Children's Hospital (n=16) and Children's Hospital of Los Angeles (n=50) when training the model for a total of 135 MIS-C patients during internal validation ( Table 1) . External validation was performed using MIS-C clinical data (n=175) enrolled from May 14, 2020 to June 18, 2021 from the following sites: Boston Children's Hospital (n=50), Children's nc Hospital (n=42), and the CHARMS consortium (n=83), a 14-site multicenter database of housed at UCSD. In a comparison of laboratory data among the groups, MIS-C patients had higher band counts, lower sodium levels, lower platelet counts, and higher C-reactive protein (p < 0.0001) compared to the FC and KD cohorts, consistent with prior reports 1,4 ( Table 1) . The 10-fold cross validation results for Stage 1 and 2 are shown in Table 2 . The neural network in Stage 1 had similar accuracy, area under the receiver operating characteristic curve (AUC), positive predictive value (PPV), negative predictive value (NPV), false positive rate (FPR), and false negative rate (FNR) compared to the logistic regression baseline in the validation set when classifying samples as MIS-C or not MIS-C. In Stage 2, the neural network compared favorably to the logistic regression baseline in terms of accuracy, PPV, and FPR when classifying samples as FC or KD based on thresholds set at 95% sensitivity for KD samples ( Table 2) . We chose 95% sensitivity based on clinician feedback to avoid missing true positive subjects. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. We selected the model with the highest accuracy during the 10-fold cross-validation at each stage to use in the final model. To ensure model generalizability and similar performance across external sites, we constructed a conformal prediction framework using the training samples from the final model 12 . Briefly, we selected the parsimonious combination of missingness and risk score with the highest weighted F1 score to construct the conformal trust sets (Supplementary feature representations that could not be calculated using logistic regression. In addition, the majority of patients at UCSD had a complete blood count with manual differential, but the external sites had a significant proportion of automated differentials. The neural networks were able to adjust for the difference between manual complete blood counts and automated differential counts effectively by incorporating an indicator variable as input to the model. Devising a diagnostic test for two diseases for which there is no gold standard test presents special challenges. As a sensitivity analysis, we tested KD patients with coronary artery aneurysms and MIS-C patients who had a reduced left ventricular ejection fraction as All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint characteristic patient subsets who were unlikely to be misclassified by clinicians. The final model correctly assigned 94% of the 164 KD patients with coronary artery aneurysms and 95% of the MIS-C patients with reduced ejection fraction (Supplementary Figure 1) . To determine how the features contributed to the model predictions, we used Shapley values, specifically the Shapley Additive exPlanations (SHAP) method 13 . In Stage 1, the most important features that distinguished MIS-C vs non MIS-C patients were serum sodium, platelet count, neutrophils, and C-reactive protein (Figure 3) . The patterns observed were consistent with published reports of the laboratory testing characteristics of MIS-C patients 1, 4 . In Stage 2, changes in peripheral extremities, erythrocyte sedimentation rate, conjunctival injection, and erythema of the lips or oropharyngeal mucosa were the most important features for differentiating between FC and KD. Three of the four aforementioned features are clinical signs used by clinicians to diagnose KD, so it is not surprising that the presence of one or more of these clinical signs contributed to a higher Stage 2 risk score and higher probability of KD. The next most important features were age, with younger patients more likely to have KD, and gamma glutamyl transferase (GGT), for which higher levels indicate hepatobiliary inflammation often observed in KD 14 . We externally validated KIDMATCH using MIS-C patients from the CHARMS consortium, Boston Children's Hospital (Boston), and Children's National Hospital (CNH). Our conformal prediction framework rejected 2/83 (2.4%), 1/50 (2%), and 2/42 (4.8%) samples from the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3) . Examination of the Stage 1 risk scores for each site revealed most MIS-C patients were confidently classified as MIS-C (risk score > 0.8) (Figure 4) . Although we had only 26 MIS-C patients in the internal validation testing cohort, KIDMATCH generalized well to external MIS-C cohorts with 90% or greater accuracy at all three external sources despite missingness of 1-4 features, most often GGT. Interestingly, the predictive performance was not replicated consistently across all sites. CNH had the lowest prediction accuracy at 90%. Further investigation revealed that their laboratory values for albumin were significantly lower than the MIS-C training distribution (2.9 [2.5-3.2] (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Figure 4) . However, the model enables clinicians to explore how the relevant features are contributing to the risk score and adjust their clinical judgement accordingly. We present a machine learning model for screening patients with MIS-C, KD, or similar febrile illnesses using clinical signs and laboratory data routinely collected during the initial evaluation of these patients. To date, this is the first application of artificial intelligence to aid in the diagnosis of MIS-C and differentiate it from KD. KIDMATCH has the ability to reject test samples that are outside of the distribution in the training set, which provides a measure of confidence by statistically identifying outlier inputs. It is interpretable on a case-by-case basis by examining the most important features and whether they impact the MIS-C risk score positively or negatively. KIDMATCH showed consistent performance across different hospitals and the conformal framework identified outlier samples that would have been misclassified otherwise, thus demonstrating our algorithm can be applied in diverse clinical settings. A web-based user interface was developed using Streamlit, an open-source framework for building applications in Python, to assist clinicians with calculation of the proposed risk scores and assessment of the top factors contributing to risk (Supplementary Figure 5) . A strength of our work is the universal availability of the required features in the majority of healthcare settings and the validation using external cohorts. The only published model addressing a machine learning approach to MIS-C diagnosis includes features that may not be available in many clinical settings such as ferritin and D-dimer 15 . In addition, the model was not tested against febrile pediatric control patients and was not externally validated. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We recognize limitations to our work due to the limited availability of FC and KD data for external validation. There is no gold standard for KD or MIS-C diagnosis. Thus, we cannot exclude some degree of misdiagnosis in either the training or test set. However, the validation performance demonstrated internal consistency with the signs and laboratory tests used by KIDMATCH. It is unknown how the model would perform on FC and KD patients from other hospitals as we were unable to obtain these data. The thresholds established during internal validation may not be generalizable to different sites and shifting the threshold may be required to adjust for different prevalence rates. However, the high model AUC means that the model can be used to effectively prioritize febrile patients for further evaluation of MIS-C or KD. A key step for deployment will be to establish standardized conditions for use so the algorithm is applied to the appropriate patients. The current algorithm is only optimized for laboratory test values collected at the time of initial evaluation, and it is unknown how it would perform with data collected at a later timepoint. It is also unknown how end users should deal with patients flagged as indeterminate, but a possible solution could be to order more specialized tests such as ferritin, troponin, BNP/NT-proBNP, and D-dimer as well as IgG antibody to SARS-CoV-2 as is routine practice for suspected MIS-C patients 16 . Based on these data, the proposed algorithm is a generalizable and trustworthy tool for the diagnosis of MIS-C and KD during the initial evaluation of the patient. Future work includes retrospective validation on external FC and KD patients and prospective validation on MIS-C patients as well as implementing KIDMATCH within the clinical workflow. As the first All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint externally validated machine learning solution for the diagnosis of MIS-C, KIDMATCH has the potential to aid frontline clinicians and improve patient outcomes through timely diagnosis. De-identified data has been compiled from multiple sites across the United States. Requests for data will require approval from UCSD and partner institutions independently. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Stage 2 in terms of AUC. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 24 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint were classified as MIS-C, and patients with lower risk scores were passed to Stage 2. C) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Atypical lymphocytes, % 0 (0-1) 0 (0-1) 1 (0-3) <0.0001 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Children's National Hospital 3 (7.5%) 1 (2.5%) 36 (90%) 40 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 (n=20) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 31 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 ort ed es he All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Supplementary Figure All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint B) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Group by site number. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.21268280 doi: medRxiv preprint Harahsheh -Children's National Hospital Michelle Hite -Children's Hospital Colorado Jone -Children's Hospital Colorado Lerraughn Morgan -Valley Children's Healthcare Allison Rometo -UPMC Children's Hospital of Pittsburgh Margalit Rosenkranz -UPMC Children's Hospital of Pittsburgh Children's Hospital of Chicago All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 Multisystem Inflammatory Syndrome in U.S. Children and Adolescents Multisystem Inflammatory Syndrome in Children in New York State COVID-19 and multisystem inflammatory syndrome in children and adolescents Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. COVID Data Tracker Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Survey From the International Kawasaki Disease Registry Artificial intelligence sepsis prediction algorithm learns to say "I don't know A Unified Approach to Interpreting Model Predictions Abnormal Liver Panel in Acute Kawasaki Disease Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Emergency Preparedness and Response This work was supported by NIH grants (R61HD105590 to J.C.B, R01HL140898 to J.C.B. and A.H.T) and a grant from the Patient-Centered Outcomes Research Institute (CER-1602-3447 to J.C.B). J.Y.L. was supported by a predoctoral fellowship from the National Library of Medicine (T15LM011271). We would like to thank Supreeth Shashikumar, PhD, for technical advice and support with the conformal prediction framework. Supplementary Figure All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.